CA3013051A1 - Antigen binding proteins that bind pd-l1 - Google Patents

Antigen binding proteins that bind pd-l1 Download PDF

Info

Publication number
CA3013051A1
CA3013051A1 CA3013051A CA3013051A CA3013051A1 CA 3013051 A1 CA3013051 A1 CA 3013051A1 CA 3013051 A CA3013051 A CA 3013051A CA 3013051 A CA3013051 A CA 3013051A CA 3013051 A1 CA3013051 A1 CA 3013051A1
Authority
CA
Canada
Prior art keywords
seq
antibody
variable domain
amino acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3013051A
Other languages
English (en)
French (fr)
Inventor
Heyue Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3013051A1 publication Critical patent/CA3013051A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3013051A 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1 Pending CA3013051A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
US62/288,912 2016-01-29
PCT/US2017/015429 WO2017132562A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Publications (1)

Publication Number Publication Date
CA3013051A1 true CA3013051A1 (en) 2017-08-03

Family

ID=59386438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013051A Pending CA3013051A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Country Status (18)

Country Link
US (4) US10118963B2 (enExample)
EP (1) EP3408400B1 (enExample)
JP (3) JP6883590B2 (enExample)
KR (1) KR20190026642A (enExample)
CN (2) CN109715821B (enExample)
AU (1) AU2017212717B2 (enExample)
BR (1) BR112018015480A2 (enExample)
CA (1) CA3013051A1 (enExample)
CL (1) CL2018002034A1 (enExample)
EA (1) EA037855B1 (enExample)
ES (1) ES2986360T3 (enExample)
IL (1) IL260846B2 (enExample)
MX (2) MX2018009228A (enExample)
NZ (1) NZ745357A (enExample)
PH (1) PH12018501611A1 (enExample)
SG (1) SG11201806496SA (enExample)
TW (1) TWI760323B (enExample)
WO (1) WO2017132562A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102410078B1 (ko) * 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2018009228A (es) * 2016-01-29 2019-07-08 Sorrento Therapeutics Inc Proteínas de unión a antigeno que se unen a pd-l1.
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
SG11202009791VA (en) 2018-04-09 2020-11-27 Origincell Therapeutics Co Ltd Anti-pd-l1 antibody and use thereof
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20210046725A (ko) 2018-08-20 2021-04-28 1글로브 바이오메디칼 씨오., 엘티디. 신규 암 면역요법 항체 조성물
EP3893902B1 (en) * 2018-12-11 2024-10-23 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of pd-l1 activity or expression for use in the treatment of serrated colorectal cancer
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
CN114025757B (zh) 2019-04-18 2025-05-13 Qlsf生物治疗药物公司 人源化抗pd-l1抗体
JP2022521958A (ja) * 2019-08-29 2022-04-13 榮昌生物制薬（烟台）股▲フン▼有限公司 抗ｐｄ－ｌ１抗体及びその応用
IL299289A (en) * 2020-06-26 2023-02-01 Sorrento Therapeutics Inc Oncolytic herpes simplex viruses (HSV) expressing immunomodulatory proteins
JP2023539369A (ja) 2020-09-02 2023-09-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 抗体－ナノ粒子複合体、ならびにその作製および使用方法
KR102557472B1 (ko) 2020-11-16 2023-07-21 주식회사 이뮨온시아 면역항암제에 대한 치료 반응성을 예측하기 위한 바이오마커 및 이의 용도
TW202305006A (zh) 2021-05-07 2023-02-01 南韓商益免安協公司 與ｃｄ４７及ｐｄ—ｌ１特異性結合的雙特異性抗體
JP2024522623A (ja) 2021-06-09 2024-06-21 ソレント・セラピューティクス・インコーポレイテッド リンパ管マイクロニードル送達デバイスを介した抗ｐｄ－１または抗ｐｄ－ｌ１治療剤の投与によるがんの処置方法
CA3267341A1 (en) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Specific chimeric antigen receptors for a citrullinated antigen to target regulatory T lymphocytes for the treatment of hidradenitis suppurativa
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
WO2025183487A1 (en) * 2024-02-29 2025-09-04 Yuhan Corporation Anti-tigit/anti-pd-l1 bispecific antibody and use thereof
EP4656658A1 (en) 2024-04-13 2025-12-03 Immuneoncia Therapeutics, Inc. Neoadjuvant therapy using pd-l1 inhibitor for treating cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ATE225801T1 (de) 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2008150577A1 (en) 2007-06-01 2008-12-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102410078B1 (ko) * 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
WO2014055897A2 (en) * 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
HK1221964A1 (zh) * 2013-05-31 2017-06-16 Sorrento Therapeutics, Inc. 与pd-1结合的抗原结合蛋白
CA2944767C (en) * 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
MX2018009228A (es) * 2016-01-29 2019-07-08 Sorrento Therapeutics Inc Proteínas de unión a antigeno que se unen a pd-l1.

Also Published As

Publication number Publication date
KR20190026642A (ko) 2019-03-13
EA201891709A1 (ru) 2019-01-31
US20170218066A1 (en) 2017-08-03
WO2017132562A1 (en) 2017-08-03
EA037855B1 (ru) 2021-05-27
JP2019507183A (ja) 2019-03-14
CL2018002034A1 (es) 2019-03-15
EP3408400A1 (en) 2018-12-05
JP2022095910A (ja) 2022-06-28
EP3408400A4 (en) 2019-11-27
MX2022011659A (es) 2022-10-13
US20190092861A1 (en) 2019-03-28
NZ745357A (en) 2025-08-29
MX2018009228A (es) 2019-07-08
PH12018501611A1 (en) 2019-04-08
US11919952B2 (en) 2024-03-05
US20240190959A1 (en) 2024-06-13
US10919964B2 (en) 2021-02-16
WO2017132562A8 (en) 2017-09-08
CN109715821A (zh) 2019-05-03
TW201736400A (zh) 2017-10-16
SG11201806496SA (en) 2018-08-30
TWI760323B (zh) 2022-04-11
JP2021102633A (ja) 2021-07-15
IL260846B (en) 2022-10-01
IL260846B2 (en) 2023-02-01
US20210147539A1 (en) 2021-05-20
EP3408400B1 (en) 2024-06-26
JP7140867B2 (ja) 2022-09-21
ES2986360T3 (es) 2024-11-11
IL260846A (enExample) 2018-09-20
JP6883590B2 (ja) 2021-06-09
EP3408400C0 (en) 2024-06-26
US10118963B2 (en) 2018-11-06
CN109715821B (zh) 2022-09-06
BR112018015480A2 (pt) 2019-05-21
CN116333124A (zh) 2023-06-27
AU2017212717A1 (en) 2018-09-06
AU2017212717B2 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US11919952B2 (en) Antigen binding proteins that bind PD-L1
US11878058B2 (en) Antigen binding proteins that bind PD-L1
US11242391B2 (en) Antigen binding proteins that bind PD-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220124

EEER Examination request

Effective date: 20220124

EEER Examination request

Effective date: 20220124

EEER Examination request

Effective date: 20220124

EEER Examination request

Effective date: 20220124

EEER Examination request

Effective date: 20220124